Analyst upgrades typically lead to a positive short-term reaction in the stock market as they reflect an improved outlook on the company's future performance. Given the upgrade from Hold to Buy, it's likely that investors will view this as a strong endorsement of Eli Lilly's potential, potentially driving up the stock price in the short term.